CN101463085B - Gene engineering monoclonal antibody combined with A-beta oligomer specificity - Google Patents
Gene engineering monoclonal antibody combined with A-beta oligomer specificity Download PDFInfo
- Publication number
- CN101463085B CN101463085B CN2009100769959A CN200910076995A CN101463085B CN 101463085 B CN101463085 B CN 101463085B CN 2009100769959 A CN2009100769959 A CN 2009100769959A CN 200910076995 A CN200910076995 A CN 200910076995A CN 101463085 B CN101463085 B CN 101463085B
- Authority
- CN
- China
- Prior art keywords
- antibody
- seq
- monoclonal antibody
- ser
- beta
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 101800001718 Amyloid-beta protein Proteins 0.000 title claims abstract description 78
- 108090000623 proteins and genes Proteins 0.000 title claims description 16
- 238000002360 preparation method Methods 0.000 claims abstract description 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 9
- 150000001413 amino acids Chemical class 0.000 claims description 18
- 235000001014 amino acid Nutrition 0.000 claims description 8
- 238000001514 detection method Methods 0.000 claims description 8
- 235000018102 proteins Nutrition 0.000 claims description 7
- 102000004169 proteins and genes Human genes 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 230000008034 disappearance Effects 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 206010012289 Dementia Diseases 0.000 claims description 2
- 239000003153 chemical reaction reagent Substances 0.000 claims description 2
- 230000003712 anti-aging effect Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 12
- 238000002474 experimental method Methods 0.000 abstract description 10
- 231100000331 toxic Toxicity 0.000 abstract description 6
- 230000002588 toxic effect Effects 0.000 abstract description 6
- 241000588724 Escherichia coli Species 0.000 abstract description 5
- 206010016654 Fibrosis Diseases 0.000 abstract description 5
- 230000004761 fibrosis Effects 0.000 abstract description 5
- 230000002776 aggregation Effects 0.000 abstract description 4
- 238000004220 aggregation Methods 0.000 abstract description 4
- 239000002131 composite material Substances 0.000 abstract 1
- 230000000688 enterotoxigenic effect Effects 0.000 abstract 1
- 239000002953 phosphate buffered saline Substances 0.000 description 22
- 230000027455 binding Effects 0.000 description 15
- 239000000178 monomer Substances 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 11
- 238000000034 method Methods 0.000 description 10
- 239000006228 supernatant Substances 0.000 description 10
- YMTLKLXDFCSCNX-BYPYZUCNSA-N Ser-Gly-Gly Chemical compound OC[C@H](N)C(=O)NCC(=O)NCC(O)=O YMTLKLXDFCSCNX-BYPYZUCNSA-N 0.000 description 9
- 239000000427 antigen Substances 0.000 description 9
- 102000036639 antigens Human genes 0.000 description 9
- 108091007433 antigens Proteins 0.000 description 9
- 108010001064 glycyl-glycyl-glycyl-glycine Proteins 0.000 description 9
- 238000004321 preservation Methods 0.000 description 9
- 238000012216 screening Methods 0.000 description 9
- 238000002965 ELISA Methods 0.000 description 8
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- SOEGEPHNZOISMT-BYPYZUCNSA-N Gly-Ser-Gly Chemical compound NCC(=O)N[C@@H](CO)C(=O)NCC(O)=O SOEGEPHNZOISMT-BYPYZUCNSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 229920001213 Polysorbate 20 Polymers 0.000 description 6
- SFTZWNJFZYOLBD-ZDLURKLDSA-N Ser-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CO SFTZWNJFZYOLBD-ZDLURKLDSA-N 0.000 description 6
- ANHVRCNNGJMJNG-BZSNNMDCSA-N Tyr-Tyr-Cys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CS)C(=O)O)N)O ANHVRCNNGJMJNG-BZSNNMDCSA-N 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 6
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 208000024827 Alzheimer disease Diseases 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- JSHWXQIZOCVWIA-ZKWXMUAHSA-N Asp-Ser-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O JSHWXQIZOCVWIA-ZKWXMUAHSA-N 0.000 description 4
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 4
- 206010039966 Senile dementia Diseases 0.000 description 4
- OLKICIBQRVSQMA-SRVKXCTJSA-N Ser-Ser-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O OLKICIBQRVSQMA-SRVKXCTJSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000013016 damping Methods 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 238000010353 genetic engineering Methods 0.000 description 4
- 108010089804 glycyl-threonine Proteins 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 108010073969 valyllysine Proteins 0.000 description 4
- YYSWCHMLFJLLBJ-ZLUOBGJFSA-N Ala-Ala-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O YYSWCHMLFJLLBJ-ZLUOBGJFSA-N 0.000 description 3
- VCSABYLVNWQYQE-SRVKXCTJSA-N Ala-Lys-Lys Chemical compound NCCCC[C@H](NC(=O)[C@@H](N)C)C(=O)N[C@@H](CCCCN)C(O)=O VCSABYLVNWQYQE-SRVKXCTJSA-N 0.000 description 3
- VCSABYLVNWQYQE-UHFFFAOYSA-N Ala-Lys-Lys Natural products NCCCCC(NC(=O)C(N)C)C(=O)NC(CCCCN)C(O)=O VCSABYLVNWQYQE-UHFFFAOYSA-N 0.000 description 3
- XUCHENWTTBFODJ-FXQIFTODSA-N Ala-Met-Ala Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(O)=O XUCHENWTTBFODJ-FXQIFTODSA-N 0.000 description 3
- AWNAEZICPNGAJK-FXQIFTODSA-N Ala-Met-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(O)=O AWNAEZICPNGAJK-FXQIFTODSA-N 0.000 description 3
- HOVPGJUNRLMIOZ-CIUDSAMLSA-N Ala-Ser-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](C)N HOVPGJUNRLMIOZ-CIUDSAMLSA-N 0.000 description 3
- ARHJJAAWNWOACN-FXQIFTODSA-N Ala-Ser-Val Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O ARHJJAAWNWOACN-FXQIFTODSA-N 0.000 description 3
- VKKYFICVTYKFIO-CIUDSAMLSA-N Arg-Ala-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCN=C(N)N VKKYFICVTYKFIO-CIUDSAMLSA-N 0.000 description 3
- OVVUNXXROOFSIM-SDDRHHMPSA-N Arg-Arg-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)N)C(=O)O OVVUNXXROOFSIM-SDDRHHMPSA-N 0.000 description 3
- AOHKLEBWKMKITA-IHRRRGAJSA-N Arg-Phe-Ser Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N AOHKLEBWKMKITA-IHRRRGAJSA-N 0.000 description 3
- MKJBPDLENBUHQU-CIUDSAMLSA-N Asn-Ser-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O MKJBPDLENBUHQU-CIUDSAMLSA-N 0.000 description 3
- QNFRBNZGVVKBNJ-PEFMBERDSA-N Asp-Ile-Gln Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC(=O)O)N QNFRBNZGVVKBNJ-PEFMBERDSA-N 0.000 description 3
- USNJAPJZSGTTPX-XVSYOHENSA-N Asp-Phe-Thr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O USNJAPJZSGTTPX-XVSYOHENSA-N 0.000 description 3
- MNQMTYSEKZHIDF-GCJQMDKQSA-N Asp-Thr-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O MNQMTYSEKZHIDF-GCJQMDKQSA-N 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- OYTPNWYZORARHL-XHNCKOQMSA-N Gln-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCC(=O)N)N OYTPNWYZORARHL-XHNCKOQMSA-N 0.000 description 3
- NKCZYEDZTKOFBG-GUBZILKMSA-N Gln-Gln-Arg Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O NKCZYEDZTKOFBG-GUBZILKMSA-N 0.000 description 3
- XZLLTYBONVKGLO-SDDRHHMPSA-N Gln-Lys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(=O)N)N)C(=O)O XZLLTYBONVKGLO-SDDRHHMPSA-N 0.000 description 3
- MIWJDJAMMKHUAR-ZVZYQTTQSA-N Glu-Trp-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CCC(=O)O)N MIWJDJAMMKHUAR-ZVZYQTTQSA-N 0.000 description 3
- YQPFCZVKMUVZIN-AUTRQRHGSA-N Glu-Val-Gln Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O YQPFCZVKMUVZIN-AUTRQRHGSA-N 0.000 description 3
- IWAXHBCACVWNHT-BQBZGAKWSA-N Gly-Asp-Arg Chemical compound NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N IWAXHBCACVWNHT-BQBZGAKWSA-N 0.000 description 3
- BYYNJRSNDARRBX-YFKPBYRVSA-N Gly-Gln-Gly Chemical compound NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O BYYNJRSNDARRBX-YFKPBYRVSA-N 0.000 description 3
- MIIVFRCYJABHTQ-ONGXEEELSA-N Gly-Leu-Val Chemical compound [H]NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O MIIVFRCYJABHTQ-ONGXEEELSA-N 0.000 description 3
- PDUHNKAFQXQNLH-ZETCQYMHSA-N Gly-Lys-Gly Chemical compound NCCCC[C@H](NC(=O)CN)C(=O)NCC(O)=O PDUHNKAFQXQNLH-ZETCQYMHSA-N 0.000 description 3
- IFHJOBKVXBESRE-YUMQZZPRSA-N Gly-Met-Gln Chemical compound CSCC[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)CN IFHJOBKVXBESRE-YUMQZZPRSA-N 0.000 description 3
- WNZOCXUOGVYYBJ-CDMKHQONSA-N Gly-Phe-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CN)O WNZOCXUOGVYYBJ-CDMKHQONSA-N 0.000 description 3
- LCRDMSSAKLTKBU-ZDLURKLDSA-N Gly-Ser-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)CN LCRDMSSAKLTKBU-ZDLURKLDSA-N 0.000 description 3
- PXKACEXYLPBMAD-JBDRJPRFSA-N Ile-Ser-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O)N PXKACEXYLPBMAD-JBDRJPRFSA-N 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- PMGDADKJMCOXHX-UHFFFAOYSA-N L-Arginyl-L-glutamin-acetat Natural products NC(=N)NCCCC(N)C(=O)NC(CCC(N)=O)C(O)=O PMGDADKJMCOXHX-UHFFFAOYSA-N 0.000 description 3
- AXZGZMGRBDQTEY-SRVKXCTJSA-N Leu-Gln-Met Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(O)=O AXZGZMGRBDQTEY-SRVKXCTJSA-N 0.000 description 3
- CQGSYZCULZMEDE-UHFFFAOYSA-N Leu-Gln-Pro Natural products CC(C)CC(N)C(=O)NC(CCC(N)=O)C(=O)N1CCCC1C(O)=O CQGSYZCULZMEDE-UHFFFAOYSA-N 0.000 description 3
- GPICTNQYKHHHTH-GUBZILKMSA-N Leu-Gln-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(O)=O GPICTNQYKHHHTH-GUBZILKMSA-N 0.000 description 3
- QNBVTHNJGCOVFA-AVGNSLFASA-N Leu-Leu-Glu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCC(O)=O QNBVTHNJGCOVFA-AVGNSLFASA-N 0.000 description 3
- KIZIOFNVSOSKJI-CIUDSAMLSA-N Leu-Ser-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N KIZIOFNVSOSKJI-CIUDSAMLSA-N 0.000 description 3
- IXHKPDJKKCUKHS-GARJFASQSA-N Lys-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCCCN)N IXHKPDJKKCUKHS-GARJFASQSA-N 0.000 description 3
- GQZMPWBZQALKJO-UWVGGRQHSA-N Lys-Gly-Arg Chemical compound [H]N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O GQZMPWBZQALKJO-UWVGGRQHSA-N 0.000 description 3
- AIRZWUMAHCDDHR-KKUMJFAQSA-N Lys-Leu-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O AIRZWUMAHCDDHR-KKUMJFAQSA-N 0.000 description 3
- SPSSJSICDYYTQN-HJGDQZAQSA-N Met-Thr-Gln Chemical compound CSCC[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCC(N)=O SPSSJSICDYYTQN-HJGDQZAQSA-N 0.000 description 3
- BKWJQWJPZMUWEG-LFSVMHDDSA-N Phe-Ala-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=CC=C1 BKWJQWJPZMUWEG-LFSVMHDDSA-N 0.000 description 3
- CUMXHKAOHNWRFQ-BZSNNMDCSA-N Phe-Asp-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=CC=C1 CUMXHKAOHNWRFQ-BZSNNMDCSA-N 0.000 description 3
- FGWUALWGCZJQDJ-URLPEUOOSA-N Phe-Thr-Ile Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O FGWUALWGCZJQDJ-URLPEUOOSA-N 0.000 description 3
- MGDFPGCFVJFITQ-CIUDSAMLSA-N Pro-Glu-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O MGDFPGCFVJFITQ-CIUDSAMLSA-N 0.000 description 3
- HAAQQNHQZBOWFO-LURJTMIESA-N Pro-Gly-Gly Chemical compound OC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1 HAAQQNHQZBOWFO-LURJTMIESA-N 0.000 description 3
- WTWGOQRNRFHFQD-JBDRJPRFSA-N Ser-Ala-Ile Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O WTWGOQRNRFHFQD-JBDRJPRFSA-N 0.000 description 3
- QEDMOZUJTGEIBF-FXQIFTODSA-N Ser-Arg-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(O)=O QEDMOZUJTGEIBF-FXQIFTODSA-N 0.000 description 3
- OBXVZEAMXFSGPU-FXQIFTODSA-N Ser-Asn-Arg Chemical compound C(C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CO)N)CN=C(N)N OBXVZEAMXFSGPU-FXQIFTODSA-N 0.000 description 3
- FMDHKPRACUXATF-ACZMJKKPSA-N Ser-Gln-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(O)=O FMDHKPRACUXATF-ACZMJKKPSA-N 0.000 description 3
- QYSFWUIXDFJUDW-DCAQKATOSA-N Ser-Leu-Arg Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O QYSFWUIXDFJUDW-DCAQKATOSA-N 0.000 description 3
- GJFYFGOEWLDQGW-GUBZILKMSA-N Ser-Leu-Gln Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CO)N GJFYFGOEWLDQGW-GUBZILKMSA-N 0.000 description 3
- YUJLIIRMIAGMCQ-CIUDSAMLSA-N Ser-Leu-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O YUJLIIRMIAGMCQ-CIUDSAMLSA-N 0.000 description 3
- AZWNCEBQZXELEZ-FXQIFTODSA-N Ser-Pro-Ser Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O AZWNCEBQZXELEZ-FXQIFTODSA-N 0.000 description 3
- NRUPKQSXTJNQGD-XGEHTFHBSA-N Thr-Cys-Arg Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O NRUPKQSXTJNQGD-XGEHTFHBSA-N 0.000 description 3
- LKEKWDJCJSPXNI-IRIUXVKKSA-N Thr-Glu-Tyr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 LKEKWDJCJSPXNI-IRIUXVKKSA-N 0.000 description 3
- FQPDRTDDEZXCEC-SVSWQMSJSA-N Thr-Ile-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O FQPDRTDDEZXCEC-SVSWQMSJSA-N 0.000 description 3
- IJVNLNRVDUTWDD-MEYUZBJRSA-N Thr-Leu-Tyr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O IJVNLNRVDUTWDD-MEYUZBJRSA-N 0.000 description 3
- KZSYAEWQMJEGRZ-RHYQMDGZSA-N Thr-Leu-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O KZSYAEWQMJEGRZ-RHYQMDGZSA-N 0.000 description 3
- DXPURPNJDFCKKO-RHYQMDGZSA-N Thr-Lys-Val Chemical compound CC(C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)[C@@H](C)O)C(O)=O DXPURPNJDFCKKO-RHYQMDGZSA-N 0.000 description 3
- MNYNCKZAEIAONY-XGEHTFHBSA-N Thr-Val-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O MNYNCKZAEIAONY-XGEHTFHBSA-N 0.000 description 3
- SVGAWGVHFIYAEE-JSGCOSHPSA-N Trp-Gly-Gln Chemical compound C1=CC=C2C(C[C@H](N)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O)=CNC2=C1 SVGAWGVHFIYAEE-JSGCOSHPSA-N 0.000 description 3
- MBLJBGZWLHTJBH-SZMVWBNQSA-N Trp-Val-Arg Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)=CNC2=C1 MBLJBGZWLHTJBH-SZMVWBNQSA-N 0.000 description 3
- MVFQLSPDMMFCMW-KKUMJFAQSA-N Tyr-Leu-Asn Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O MVFQLSPDMMFCMW-KKUMJFAQSA-N 0.000 description 3
- SSYBNWFXCFNRFN-GUBZILKMSA-N Val-Pro-Ser Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O SSYBNWFXCFNRFN-GUBZILKMSA-N 0.000 description 3
- WUFHZIRMAZZWRS-OSUNSFLBSA-N Val-Thr-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C(C)C)N WUFHZIRMAZZWRS-OSUNSFLBSA-N 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 108010081404 acein-2 Proteins 0.000 description 3
- 108010008685 alanyl-glutamyl-aspartic acid Proteins 0.000 description 3
- 108010069020 alanyl-prolyl-glycine Proteins 0.000 description 3
- 108010086434 alanyl-seryl-glycine Proteins 0.000 description 3
- 108010005233 alanylglutamic acid Proteins 0.000 description 3
- 108010008355 arginyl-glutamine Proteins 0.000 description 3
- 108010068380 arginylarginine Proteins 0.000 description 3
- 108010069205 aspartyl-phenylalanine Proteins 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 238000003759 clinical diagnosis Methods 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 108010078144 glutaminyl-glycine Proteins 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 108010067216 glycyl-glycyl-glycine Proteins 0.000 description 3
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Natural products NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108010020755 prolyl-glycyl-glycine Proteins 0.000 description 3
- 238000007789 sealing Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 231100000820 toxicity test Toxicity 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 2
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 2
- UGXYFDQFLVCDFC-CIUDSAMLSA-N Asn-Ser-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O UGXYFDQFLVCDFC-CIUDSAMLSA-N 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- JSLIXOUMAOUGBN-JUKXBJQTSA-N Ile-Tyr-His Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC2=CN=CN2)C(=O)O)N JSLIXOUMAOUGBN-JUKXBJQTSA-N 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- YNPNZTXNASCQKK-UHFFFAOYSA-N Phenanthrene Natural products C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- PKZIWSHDJYIPRH-JBACZVJFSA-N Trp-Tyr-Gln Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(N)=O)C(O)=O PKZIWSHDJYIPRH-JBACZVJFSA-N 0.000 description 2
- PDDJTOSAVNRJRH-UNQGMJICSA-N Val-Thr-Phe Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)[C@H](C(C)C)N)O PDDJTOSAVNRJRH-UNQGMJICSA-N 0.000 description 2
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 108010040030 histidinoalanine Proteins 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 230000032696 parturition Effects 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000000452 restraining effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- BYEAHWXPCBROCE-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-ol Chemical compound FC(F)(F)C(O)C(F)(F)F BYEAHWXPCBROCE-UHFFFAOYSA-N 0.000 description 1
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 1
- VNYMOTCMNHJGTG-JBDRJPRFSA-N Ala-Ile-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O VNYMOTCMNHJGTG-JBDRJPRFSA-N 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- GIVATXIGCXFQQA-FXQIFTODSA-N Arg-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCN=C(N)N GIVATXIGCXFQQA-FXQIFTODSA-N 0.000 description 1
- XPSGESXVBSQZPL-SRVKXCTJSA-N Arg-Arg-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O XPSGESXVBSQZPL-SRVKXCTJSA-N 0.000 description 1
- SLKLLQWZQHXYSV-CIUDSAMLSA-N Asn-Ala-Lys Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(O)=O SLKLLQWZQHXYSV-CIUDSAMLSA-N 0.000 description 1
- GXMSVVBIAMWMKO-BQBZGAKWSA-N Asn-Arg-Gly Chemical compound NC(=O)C[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CCCN=C(N)N GXMSVVBIAMWMKO-BQBZGAKWSA-N 0.000 description 1
- 102000000584 Calmodulin Human genes 0.000 description 1
- 108010041952 Calmodulin Proteins 0.000 description 1
- 102000052052 Casein Kinase II Human genes 0.000 description 1
- 108010010919 Casein Kinase II Proteins 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 1
- PKVWNYGXMNWJSI-CIUDSAMLSA-N Gln-Gln-Gln Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O PKVWNYGXMNWJSI-CIUDSAMLSA-N 0.000 description 1
- SXFPZRRVWSUYII-KBIXCLLPSA-N Gln-Ser-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(=O)N)N SXFPZRRVWSUYII-KBIXCLLPSA-N 0.000 description 1
- HVKAAUOFFTUSAA-XDTLVQLUSA-N Glu-Tyr-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C)C(O)=O HVKAAUOFFTUSAA-XDTLVQLUSA-N 0.000 description 1
- DZMVESFTHXSSPZ-XVYDVKMFSA-N His-Ala-Ser Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O DZMVESFTHXSSPZ-XVYDVKMFSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- ZGKVPOSSTGHJAF-HJPIBITLSA-N Ile-Tyr-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CO)C(=O)O)N ZGKVPOSSTGHJAF-HJPIBITLSA-N 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- JNDYEOUZBLOVOF-AVGNSLFASA-N Leu-Leu-Gln Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O JNDYEOUZBLOVOF-AVGNSLFASA-N 0.000 description 1
- SBQDRNOLGSYHQA-YUMQZZPRSA-N Lys-Ser-Gly Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)NCC(O)=O SBQDRNOLGSYHQA-YUMQZZPRSA-N 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- HHCOOFPGNXKFGR-HJGDQZAQSA-N Met-Gln-Thr Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O HHCOOFPGNXKFGR-HJGDQZAQSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 108010064696 N,O-diacetylmuramidase Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- YDTUEBLEAVANFH-RCWTZXSCSA-N Pro-Val-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]1CCCN1 YDTUEBLEAVANFH-RCWTZXSCSA-N 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- PIQRHJQWEPWFJG-UWJYBYFXSA-N Ser-Tyr-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C)C(O)=O PIQRHJQWEPWFJG-UWJYBYFXSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical class [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 108010088160 Staphylococcal Protein A Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- WYLAVUAWOUVUCA-XVSYOHENSA-N Thr-Phe-Asp Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(O)=O)C(O)=O WYLAVUAWOUVUCA-XVSYOHENSA-N 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- SGQSAIFDESQBRA-IHPCNDPISA-N Trp-Tyr-Asn Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)N SGQSAIFDESQBRA-IHPCNDPISA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 102000003802 alpha-Synuclein Human genes 0.000 description 1
- 108090000185 alpha-Synuclein Proteins 0.000 description 1
- KLOHDWPABZXLGI-YWUHCJSESA-M ampicillin sodium Chemical compound [Na+].C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C([O-])=O)(C)C)=CC=CC=C1 KLOHDWPABZXLGI-YWUHCJSESA-M 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 108010060035 arginylproline Proteins 0.000 description 1
- 108010068265 aspartyltyrosine Proteins 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 238000012407 engineering method Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 201000010235 heart cancer Diseases 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000024348 heart neoplasm Diseases 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 201000011475 meningoencephalitis Diseases 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 231100000255 pathogenic effect Toxicity 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- -1 polyoxyethylene Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000009774 resonance method Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000009991 scouring Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 235000011091 sodium acetates Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
Images
Landscapes
- Peptides Or Proteins (AREA)
Abstract
The invention relates to the technical field of engineered antibody and provides a monoclonal antibody. The variable region of heavy chain of the monoclonal antibody contains the amino acid sequences shown by SEQ ID NO.1, SEQ ID NO.2 and SEO ID NO.3; the variable region of light chain of the monoclonal antibody contains the amino acid sequences shown by SEQ ID NO.4, SEQ ID NO.5 and SEQ ID NO.6. The invention also specifically provides a humanization single-chain antibody generated by the recombinant strain of enterotoxigenic Escherichia coli with the accession number CGMCC No.2819 and the amino acid sequence of the humanization single-chain antibody is shown in SEQ ID NO.7. The antibody of the invention can be specifically bound with the A-beta oligomer, effectively inhibit the fibrosis aggregation of A-beta and obviously alleviate the toxic effect of the A-beta on cells. The invention also relates to a pharmaceutical composite containing the antibody. The antibody of the invention has strong activity, good specificity, easy preparation and wide prospect of experiment application and clinical application.
Description
Technical field
The invention belongs to the genetic engineering antibody technical field, be specifically related to and A-beta oligomer specificity bonded gene engineering monoclonal antibody, the pharmaceutical composition that the invention still further relates to this MONOCLONAL ANTIBODIES SPECIFIC FOR method and contain this monoclonal antibody.
Background technology
Studies show that the A Zihaimo disease (Alzheimer ' s Disease, be called for short AD), being commonly called as senile dementia is by avirulent amyloid-beta monomer molecule (β-Amyloid, A-beta 40/42 is hereinafter to be referred as A-beta, also can be write as A β) assemble forming the elderly that the oligomer of tool toxic action causes, mainly to form senile plaque with hypomnesis and brain be the nerve degenerative diseases (Selkoe etc. of feature, Science 1997,275,630-631; Koo etc., PNAS 1996,9989-9990).Medical statistics shows, in China and the American-European countries more than 60 years old the elderly have 5～6% to suffer from the A Zihaimo disease.This disease has been listed in and has caused dead the fourth-largest disease, is only second to heart trouble, cancer and apoplexy.China existing more than 60 years old population about 100,000,000, be 5% estimation according to population person in middle and old age dementia morbidity more than 60 years old, the whole nation has senile dementia patient about 5,000,000.This disease brings huge burden for family and society.
Experimental study in recent years proves that more and more condensing the intermediate product-A-beta oligomer that forms filament by the A-beta monomer is the main virulence factor that causes AD, rather than the previous thread aggregate (Haass that assert, C. etc., 2007, Nature reviews 8,101-112; Lesne, S, 2006, Nature 440,352-357; Shankar, G.M, 2008, Nature medicine 14,837-842).Yet, existing in the world at present detection and treatment AD antibody, be at the A-beta primary sequence mostly, be the monomeric antibody of A-beta, this antibody-like can with A-beta monomer, oligomer and filament combination simultaneously, in experimental study, pathology detection and clinical diagnosis, can not detect the real height that plays the oligomer level of pathogenic effects specifically.Simultaneously, this antibody-like easily causes severe side effect such as cerebral hemorrhage and meningoencephalitis in to the treatment of AD.
The Glabe laboratory on Science magazine in 2003, reported can with the antibody A 11 of oligomer specific combination (Kayed etc., 2003, Science 300,486-489).But this antibody is a kind of polyclonal antibody, and the amount at each antibody component of each antigenic determinant that contains in each production batch is uncontrollable, influences the comparability of detected result.And this antibody not only combines with the A-beta oligomer, and it also combines the specificity of no one-level sequence with multiple oligomer such as alpha-synuclein, Prion albumen, Regular Insulin, N,O-Diacetylmuramidases.
Single-chain antibody (single chain FV, ScFv) being an important function of gene engineered antibody, is the recombinant protein that utilizes gene engineering method that antibody heavy chain variable region (VH) gene and variable region of light chain (VL) the gene connection peptides by one section about 5～25 amino acid (linker) is connected to form on dna level.The C-terminal of single-chain antibody can be introduced structures such as halfcystine tail, casein kinase 2 enzyme substrates tail, E tail, help other molecule of mark and coupling, also can introduce calmodulin tail, c-myc tail, staphylococcal protein A,SPA tail, lipid label, Histidine tail etc., make expression product be easy to detect and purifying.
Single-chain antibody has a series of characteristics of self:
(1) only contains the V district of antibody, can keep more complete antigen binding site;
(2) lack the Fc section, do not combine, help being used for clinical as the drug targeting carrier with non-target cell;
(3) immunogenicity is low, is used for human body and is difficult for producing anti-foreign protein reaction;
(4) molecular weight is little, easily penetration rate of blood tube wall, tissue and solid tumor;
(5) the circulation of blood transformation period is short in the body, easily gets rid of from circulation of blood;
(6) 3 ' end at its gene connects the appropriate purpose molecule, as: enzyme, toxin, medicine etc. can make up bifunctional antibody;
(7) only combine not activating complement mediated cell immunity with antigen;
(8) be easy to genetic manipulation and genetically engineered mass production.
In recent years, single-chain antibody becomes one of focus in the genetic engineering antibody research field gradually, is demonstrating great potential aspect the clinical diagnosis of disease and the treatment.
At present, rarely seen in the world have a report about the single-chain antibody scFv of specific combination A-beta oligomer (Zameer A etc., 2008, J Mol Biol.384:917-928), and the avidity of this scFv and A-beta oligomer is lower.Though other has an antibody-like NU1, NU2 and NU4 to combine not obvious with the A-beta monomer, but they can combine with A-beta oligomer and filament simultaneously, thereby influence to the detection of A-beta oligomer in the sample (referring to Lambert etc., 2007, Journal ofneurochemistry 100,23-35).Up to the present, domesticly do not see the monoclonal antibody of specific combination A-beta oligomer or the report of single-chain antibody as yet.
Summary of the invention
The invention solves existing antibody while and A-beta monomer, oligomer and filament bonded technical problem, use phage display technology and successfully filter out and specially combine with the A-beta oligomer, and not with A-beta monomer and filament bonded monoclonal antibody.Monoclonal antibody of the present invention and A-beta oligomer specificity bonded characteristic and A-beta primary structure are irrelevant, and it plays a role by combining with the peculiar space multistory epitope of A-beta oligomer.
A-beta oligomer of the present invention is the oligomer that is formed by two to tens the A-beta monomer aggregation that do not wait, and intermolecularly mainly combines with hydrogen bond and hydrophobic bond, and molecular weight does not wait from 9kDa to 100kDa.Its space multistory epitope up to now as yet the someone inquire into clear.
On the one hand, the invention provides the monoclonal antibody of a specific specificity in conjunction with the A-beta oligomer, comprise variable region of heavy chain and variable region of light chain, variable region of heavy chain contains the aminoacid sequence shown in SEQ ID NO.1, SEQ ID N0.2 and the SEO IDNO.3, and variable region of light chain contains the aminoacid sequence shown in SEQ ID NO.4, SEQ ID NO.5 and the SEQID NO.6.
" antibody " of the present invention should be interpreted as containing any specificity binding factor with required specific binding domains.Thereby the function equivalent and the homologue of homologous antibody fragment, derivative, humanized antibody and antibody with it contained in this term, also comprises any polypeptide that contains the antigen binding domains, no matter is natural or synthetic the generation.The example of antibody is immunoglobulin (Ig) hypotype (as IgG, IgE, IgM, IgD and IgA) and hypotype subclass thereof; Also can be to comprise the fragment of antigen binding domains such as Fab, scFv, Fv, dAb, Fd; With double-stranded antibody (diabodies).Fusion to mosaic molecule or equivalent another polypeptide, that comprise the antigen binding domains is also included within wherein.The cloning and expression of chimeric antibody is described in EP.A-0120694 and EP.A.0125023.
Antibody can be modified by many modes, and available DNA recombinant technology produces other antibody or the chimeric molecule that keeps original antibodies specific.This technology can comprise that constant region or constant region that the DNA with the immune globulin variable region of encoding antibody or complementarity-determining region (CDRs) introduces different immunoglobulin (Ig)s add framework region.Referring to, EP.A.184187, GB 2188638A or .EP.A.239400.Can also carry out genetic mutation or other change to other cell of hybridoma or generation antibody, this can change or not change the binding specificity of the antibody that produces.
Monoclonal antibody provided by the invention can be humanized antibody, and it also contains the framework region of people's antibody.
Monoclonal antibody provided by the invention can also be a single-chain antibody.
In the specific embodiment of the present invention, the invention provides the single-chain antibody W8 of specificity in conjunction with the A-beta oligomer, its aminoacid sequence is shown in SEQ ID NO.7, its variable region of heavy chain contains the aminoacid sequence shown in SEQ ID NO.1, SEQ ID NO.2 and the SEO ID NO.3, and variable region of light chain contains the aminoacid sequence shown in SEQ IDNO.4, SEQ ID NO.5 and the SEQ ID NO.6.
Monoclonal antibody of the present invention comprises heavy chain and light chain " variable region ", and some part of variable region is different on sequence in term used herein " variable " the expression antibody, and it has formed combination and the specificity of various specific antibodies to its specific antigen.Yet mutability is not evenly distributed in the whole antibody variable region.It concentrates on and is called complementary determining region in light chain and the variable region of heavy chain or highly becomes in three fragments in the district.Part conservative in the variable region is called framework region (FR).CDR in every chain closely is close together by the FR district and has formed the antigen-binding site of antibody with the CDR of another chain.
Hypervariable region CDR1, the CDR2 and CDR3 and catenation sequence of monoclonal antibody of the present invention in heavy chain and light chain, other is a framework region.Framework region can be replaced by other sequences under in conjunction with the impregnable condition of required three-dimensional structure, and the molecular basis of antibodies specific mainly comes from its hypervariable region CDR1, CDR2 and CDR3, and these zones are and antigen bonded key position.For keeping preferred binding characteristic, the sequence of CDR should keep as far as possible, yet, may need some amino acid changes to make the binding characteristic optimization, those skilled in the art can reach this purpose with standing procedure.
In the specific embodiment of the present invention, at random one or several amino acid of W8 framework region being suddenlyd change respectively, lacks or adding one or several amino acid toward framework region does not influence antibody activity.As 78S being sported A and 172Q being sported the antibody W8-1 (its aminoacid sequence is shown in SEQ ID NO.8) that N forms, its activity is unaffected; Or with the 26A disappearance, or behind 87N, add G, or adding L does not all influence antibody activity behind 205D.
One or several amino acid in the W8 hypervariable region suddenlyd change respectively, lacks or add one or several amino acid and do not influence antibody activity sometimes toward the hypervariable region, as 160A is sported L, 185H sports the antibody W8-2 (its aminoacid sequence is shown in SEQ ID NO.9) that S forms, and its antibody activity is unaffected; Or with the 69G disappearance, or, behind 185H, add N with the 191S disappearance, adding G behind 107D does not all influence antibody activity.
Monoclonal antibody of the present invention is to separate to obtain from the phage antibody library of expressing more than one hundred million kinds of single-chain antibodies at phage surface respectively.Be about to the A-beta oligomer and be coated on the immune pipe, phage antibody library is added in the test tube, flush away is not attached to the phage on the immune pipe, breeds with the phage of pancreatin elution of bound and to it then, carries out 4 screenings of taking turns in the same way.Last is taken turns phage transfection Escherichia coli HB2151 under the wash-out, identify with the ELISA method and express the positive colony that produces soluble single-chain antibody.
The positive colony of the prepared single-chain antibody W8 that the specific embodiment of the invention provides, now carry out preservation in China Committee for Culture Collection of Microorganisms common micro-organisms center (DSMZ of institute of microbiology of the Chinese Academy of Sciences), the address is the Datun Road, Chaoyang District, Beijing City, classification called after colon bacillus Escherichia coli, preservation date is on December 22nd, 2008, and deposit number is CGMCC No.2819.
Being used for the also available hybridoma method of monoclonal antibody of the present invention makes, because the dna sequence dna of code book invention humanized antibody can be used conventional means well known to those skilled in the art, as obtaining according to aminoacid sequence synthetic disclosed by the invention or with the amplification of PCR method, thereby also available recombinant DNA method, available the whole bag of tricks well known in the art is connected into this sequence in the suitable expression vector.At last, under the condition that is fit to antibody expression of the present invention, cultivate the host cell that transforms gained, those skilled in the art use the conventional separation and purification means purifying of knowing and obtain monoclonal antibody of the present invention then.
In the specific embodiment of the present invention, specificity provided by the invention is in conjunction with the antibody W8 of A-beta oligomer, and molecular weight is about 29kDa.Binding constant k between W8 and A-beta 42 oligomer
a=4.02 * 10
3M
-1s
-1, dissociation constant k
d=3.08 * 10
-5s
-1, affinity constant k
D=7.66 * 10
-8M.
With W8 as identification antibody, horseradish peroxidase (HRP) mark can with the 9E10 of W8 specific combination as second antibody, can detect the A-beta oligomer of 2.2nM in the sample or 5nM respectively with enzyme-linked immunosorbent assay (ELISA) or immunodotting (Dot-blot) experiment.Can specially detect the content of nmol level A-beta oligomer in the sample based on antibody of the present invention, those of ordinary skill in the art can predict, and described antibody can be used to detect the A-beta oligomer in scientific experiment and clinical detection.
In the specific embodiment of the present invention, the gathering of A-beta test shows that W8 can effectively suppress the fibrosis gathering of A-beta.The neurocyte toxicity test shows that W8 can obviously reduce the toxic action of A-beta to neurocyte, based on above-mentioned discovery, those of ordinary skill in the art can predict this monoclonal antibody or contain the pharmaceutical composition of this monoclonal antibody can be by specificity in conjunction with the A-beta oligomer, suppress the fibrosis gathering of A-beta and reduce the toxic action of A-beta, thereby realize the purpose of prevention and treatment senile dementia neurocyte.And can predict, use molecule, can avoid complete antibody serious side effects such as meningitis that patient AD brought, hematencephalons only for complete antibody 1/5 and when not containing segmental W8 prevention of Fc and treatment senile dementia.
Pharmaceutical composition provided by the invention contains the pharmaceutically monoclonal antibody of the present invention and the pharmaceutically acceptable carrier of significant quantity.Term used herein " pharmaceutically acceptable " is meant that they can not produce disadvantageous, hypersensitive or other untoward reaction when carrier molecule body and composition suitably give the animal or human." pharmaceutically acceptable carrier " used herein should be compatible with monoclonal antibody of the present invention, can can not reduce the effect of pharmaceutical composition with its blend under normal conditions significantly, can be used as some materials of pharmaceutically acceptable carrier or its component.Object lesson can be carbohydrate, starch, Mierocrystalline cellulose and derivative thereof, stablizer, antioxidant, sanitas, apirogen water, etc. ooze salts solution and phosphate buffered saline buffer etc.
Pharmaceutical composition of the present invention can be made various formulations as required, and can by the doctor according to patient's kind, age, body weight and roughly factor such as disease condition, administering mode determine the useful dosage of patient is used.
Monoclonal antibody of the present invention has the following advantages:
1, specially combines, and do not combine with A-beta monomer and filament with the A-beta oligomer;
2, monoclonal antibody and antigen-binding specificity are good,
3, single-chain antibody lacks the Fc section, does not combine with non-target cell; Antibody molecule is less, less than 1/5 of complete antibody molecule, is easier to pass hemato encephalic barrier performance curative effect;
4, A-beta gathering test and neurocyte toxicity test show that described antibody can effectively suppress the fibrosis gathering of A-beta, and obviously reduce the toxic action of A-beta to neurocyte;
5, utilize phage expression antibody production height, active strong, specificity is good, is easy to screening.
Monoclonal antibody of the present invention has broad application prospects as the special preparation of A-beta oligomer and the immunological reagent for the treatment of as AD in clinical diagnosis, the experiment test sample.
Description of drawings
Fig. 1 detects W8 and A-beta oligomer bonded ELISA experimental result picture;
The binding characteristic of W8 and various form A-beta is compared in Fig. 2 Dot-Blot experiment, and mon represents the A-beta monomer, and oli represents the A-beta oligomer, and fib represents the A-beta filament;
Fig. 3 W8 assembles the statistics figure that suppresses experiment to A-beta 42;
Fig. 4 W8 suppresses the statistics figure of experiment to A-beta 42 cytotoxicities.
Embodiment
Before describing embodiments of the present invention in detail, be to be understood that application of the present invention is not limited to the following example, the present invention also can carry out with other embodiment.
The preparation of embodiment 1A-beta oligomer
A-beta monomer (available from the American Peptide company of the U.S.) is dissolved in HFIP (hexafluoroisopropanol is available from Sigma company), is prepared into the solution that concentration is 1mg/ml.Room-temperature water bath supersound process 10 minutes divides to install in the 1.5ml centrifuge tube, puts to allow HFIP volatilize fully in the vapor hood, and is standby in-20 ℃ of preservations.
The A-beta equilibrium at room temperature of above-mentioned processing after 10 minutes, is added DMSO (dimethyl sulfoxide (DMSO) is available from Sigma), A-beta is fully dissolved, and to make its final concentration be 1mg/ml.Get in the PBS damping fluid that a certain amount of A-beta joins pH 7.4, making A-beta concentration is 10 μ M.With this A-beta solution put 37 ℃ hatch 12 hours after, with 14000rpm centrifugal 20 minutes, abandon bottom settlings, promptly get the supernatant liquor that contains the A-beta oligomer.Confirm the formation situation of A-beta oligomer in the supernatant with atomic force microscope.
The screening of embodiment 2 positive colonies
(PBS pH=7.4) dilutes embodiment 1 gained A-beta oligomer to 10～100 μ g/mL, gets 4mL and joins in the immune pipe, and 4 ℃ of bags are spent the night to be cushioned liquid with bag.Abandon supernatant, wash pipe rapidly 3 times with PBS.Fill with the immunity pipe with 3%BSA, room temperature is vertically sealed 2h.Abandon supernatant, wash pipe rapidly 3 times with PBS.Be suspended in phage antibody library (available from the MRC center of Britain) among the 4mL 3%BSA and join immunity and manage, after room temperature is put upside down and hatched 1h, vertically hatch 1h.With the PBS of 0.1%Twenn-20 washing 10 times (second take turns screening and with after scouring 20 times).After PBS blotted, add 500 μ L pancreatin-PBS eluant solution phage, room temperature is put upside down and is hatched 10min.In the e. coli tg1 (available from the MRC center of Britain) of 1.75mL OD600=0.4, add the phage that 250 μ L elute, hatch 30min, do not shake for 37 ℃.4 ℃ of preservations of phage that residue elutes.Get 10 respectively
4, 10
6Times diluent is applied on 2 * TY (available from Sigma company) flat board 37 ℃ of overnight incubation.With 4 ℃ of centrifugal 5min of 11600g of remaining TG1 nutrient solution,, be applied on 2 * TY flat board 37 ℃ of overnight incubation with the resuspended precipitation of 100 μ L substratum.
In the flat board that covers with bacterial clone, add 2mL 2 * TY substratum, and scrape with glass stick and to get bacterium, collect the thalline suspension, get 50 μ L and join 50mL 2 * TY substratum, adding final concentration in the substratum is the Amp of 100 μ g/mL, 1% glucose (purchase give birth in Shanghai worker's biotechnology company limited), 37 ℃ are shaken to OD600=0.4 and (need 1～2h) approximately.Residue bacterium liquid adds 15% glycerine ,-70 ℃ of preservations.
In the 10mL culture, add 5 * 10
10Helper phage M13K07 (available from the MRC center of Britain) 10 μ L.Hatch for 37 ℃ and leave standstill 30min.With 4 ℃ of centrifugal 10min of bacterium liquid 3000g, resuspended being deposited in 50mL 2 * TY substratum, adding final concentration is 100 μ g/mL Amp, 50 μ g/mL kantlex (purchase give birth in Shanghai worker's biotechnology company limited) and 0.1% glucose, 30 ℃ of shaking table overnight incubation.With overnight culture 3300g, 4 ℃ of centrifugal 15min collect supernatant, add the PEG (polyoxyethylene glycol) (20%) of 1/4 volume and the mixing solutions of NaCl (2.5M), place more than 1 hour for 4 ℃ behind the abundant mixing.4 ℃ of centrifugal 30min of 3300g fully abandon clean supernatant.The resuspended 2mL PBS that is deposited in, 4 ℃ of centrifugal 10min of 11600g.Obtain the phage antibody display libraries after supernatant is the enrichment first round.Get 1 μ L phage supernatant and measure titre.
Above enrichment screening process is repeated 3 times, promptly carry out second and third, the screening of four-wheel.
Be coated onto on the flat board through the above-mentioned 4 phage-infect intestinal bacteria HB2151 (available from the MRC center of Britain) that take turns the enrichment screening, the picking mono-clonal is to 96 porocyte culture plates, add 2 * TY substratum, 200 μ L in every hole, contain the glucose of 100 μ g/mL Amp and 1% in the substratum.37 ℃ of shaking tables (300r/min) overnight incubation.2 μ L bacterium liquid are drawn in every hole, join in the other 96 new hole microbial culture plates, and 2 * TY substratum, 200 μ L are added in every hole, contain the glucose of 100 μ g/mL Amp and 1% in the substratum, and 37 ℃ of shaking tables are cultivated 3h, and OD600 reaches 0.9.Add certain volume glycerine again in first block of plate, the glycerine final concentration is 15% ,-70 ℃ of preservations.Every hole adds IPTG to final concentration 1mmol/L in second 96 orifice plate, 30 ℃ of shaking table overnight incubation.
With the antigenic solution 50 μ Ls of concentration with volume, 4 ℃ of bags were spent the night when every hole added with screening in elisa plate, and it is PBS that bag is cushioned liquid, pH=7.4.Wash plate 3 times with PBS, 37 ℃ of sealings of 3%BSA 2h, 200 μ L/ holes.Wash plate 3 times with PBS, with 4 ℃ of centrifugal 10min of 800g of above-mentioned culture, every hole is got 50 μ L and is joined in the elisa plate, behind the incubated at room 1h, with the PBS washing that contains 0.1%Tween-20 three times.Every hole adds the 9E10 (available from U.S. Santa cruz company) of the HRP mark after the 50 μ L dilution, and Dilution ratio is 1: 5000, behind the incubated at room 1h, with the PBS washing that contains 0.1%Tween-20 3 times.Every hole adds substrate solution TMB (available from U.S. Amresco company) 50 μ L, places 37 ℃ of 20min, and every then hole adds 1mmol/L sulfuric acid 50 μ L termination reactions, puts enzyme mark detector and measures OD value (wavelength 490nm).The OD value is higher than does not wrap the tentative positive clone by the clone of A-beta oligomer negative control more than 2 times, and measures its dna sequence dna and do further checking.
Use the positive colony that phage display technology screens by above-mentioned steps, now carry out preservation in China Committee for Culture Collection of Microorganisms common micro-organisms center (DSMZ of institute of microbiology of the Chinese Academy of Sciences), classification called after colon bacillus Escherichia coli, preservation date is on December 22nd, 2008, and deposit number is CGMCC No.2819.
The evaluation of embodiment 3 antibody
Abeta monomer, oligomer and fibrous body (the Abeta monomer is hatched more than 4 days for 37 ℃, and verifies through atomic force microscope) are put NC (nitrocellulose) film 3 μ L respectively.Film with after the 5%BSA sealing, is added scFv W8 and hatched 1 hour, wash film 3 times with PBS, each 5 minutes.The Protein A (available from U.S. Santa cruz company) that adds dilution in 1: 5000 was again hatched 1 hour, washed film 3 times with PBST (Tween-20 concentration is 0.1%), each 5 minutes, developed the color with DAB.Only demonstrate spot at A-beta oligomer place, the clone of display dot just is not needed clone in A-beta monomer and fibrous body.
With the evaluation of checking order of above-mentioned positive colony, the clone who meets antibody basic structure in the antibody library then is complete strand genetic engineering antibody.Sequencing primer is:
LMB3:5 '-CAG GAA ACA GCT ATG AC-3 ' (its nucleotide sequence is shown in SEQ ID NO.10)
PHEN seq:5 '-CTA TGC GGC CCC ATT CA-3 ' (its nucleotide sequence is shown in SEQ ID NO.11)
Preparation and the purifying of embodiment 4 antibody W8
(1) spawn culture
Substratum consists of 2 * YT substratum, 100 μ g/mL Amp (penbritin) (giving birth to worker's biotechnology company limited available from Shanghai), 1% glucose.The bacterial classification access 5mL culture medium culturing of Screening and Identification is spent the night, change the 500mL substratum again over to, cultivate 3h for 37 ℃, adding IPTG (isopropylthiogalactoside) (giving birth to worker's biotechnology company limited available from Shanghai) is 1mM to final concentration, 30 ℃ of overnight incubation.
(2) purifying antibody
With 4 ℃ of cultures, the centrifugal 45min of 12000g with the filtering membrane vacuum filtration of supernatant with 0.45 μ m and 0.22 μ m, fully removes bacterial debris and other impurity, concentrates supernatant to 150mL with VivaFlow50 film bag.RProtein A affinity column with PH 7.4,0.15M PBS balance GE company carries out wash-out with 0.3M pH 3.0 sodium-acetates as elutriant behind the sample upper prop, and every collection tube is collected 0.5-1ml.Eluted product is 4 ℃ of dialysed overnight in the PBS of pH 7.4.Carry out purity detecting (the about 29KD of antibody molecule amount) with sds gel electrophoresis commonly used then, with the protein concentration of antibody behind BCA test kit or other common method mensuration purifying.The present productive rate of this antibody is 40mg/L.With antibody with the small volume packing, and in-20 ℃ of preservations.
Embodiment 5 antibody affinity costant k
DWith binding constant k
aMensuration
Utilize surface plasma resonance method (SPR) antagonist k
DMeasure.Go up fixedly A-beta oligomer in detection chip (CM5) (available from Sweden Biacore company), and, W8 is diluted to the different concns gradient with the HEPES damping fluid with HEPES damping fluid equilibrate overnight.Applied sample amount is 35 μ L during detection, and flow velocity is 5 μ L/min, and data retardation time is 120 seconds behind the last sample, and detects the protein binding signal, at last with BIAcore company analysis software reading of data and calculate the K of each antibody
DValue.Record the binding constant k between W8 and the A-beta oligomer
a=4.02 * 10
3M
-1s
-1, dissociation constant k
d=3.08 * 10
-5s
-1, affinity costant K
D=7.66 * 10
-8M.
Embodiment 6ELISA detection W8 combines with the A-beta oligomer.
The A-beta oligomer bag of different concns by the enzyme linked immunological microwell plate, is put 37 ℃ of 2h, with 3%BSA37 ℃ of sealing 2h, 200 μ L/ holes.Wash plate 3 times with PBS, behind adding W8 (5 μ g/ml) the incubated at room 1h, with the PBS washing that contains 0.1%Tween-20 three times.Every hole adds the ELIAS secondary antibody (HRP-9E10) after the 100 μ L dilution, and Dilution ratio is 1: 5000, behind the incubated at room 1h, with the PBS washing that contains 0.1%Tween-20 3 times.Every hole adds substrate solution TMB 100 μ L, places 37 20min ℃, and every then hole adds 1mmol/L sulfuric acid termination reaction, measures OD value (wavelength 490nm) (* P＜0.01) on enzyme-linked immunosorbent assay instrument.The result shows that W8 can detect the A-beta oligomer of (being equivalent to every hole 6.25ng) of 2.2nM in the sample as shown in Figure 1.
Embodiment 7Dot-blot detects W8 specific combination A-beta oligomer
1) will contain concentration be the sample 2 μ l points of A-beta oligomer of 5nM to nitrocellulose membrane, put in the air and dry.
2), put room temperature 2 hours with 5% skim-milk closing membrane.
3) film is put among the PBS solution that contains scFv W8 (1 μ g/ml) or the control antibodies 4G8 (available from U.S. Signet company) and is incubated bath, put 37 ℃ 1 hour.
4) wash film 3 times, each 5 minutes with the PBS that contains 0.05%Tween-20.
5) film is joined the 9E10 (available from U.S. Santa cruz company) of HRP mark of dilution in 1: 1000, or the Protein A (1: 5000) of HRP mark put 37 ℃ 1 hour
6) washing is with 4.
7) film is joined in the DAB solution colour developing several minutes.
The result as shown in Figure 2, control antibodies 4G8 has can be in conjunction with the monomeric characteristic of A-beta, after A-beta42 was gathered into oligomer and filament, 4G8 still combined with them, and W8 can only combine with the A-beta oligomer.
Embodiment 8W8 is to A-beta42 accumulative restraining effect.
The 10 μ M A-beta42 that add or do not add W8 antibody are hatched 28h in 37 ℃.180 μ L ThT (thioflavin) solution (with the preparation of pH6.5 PB damping fluid) are added to 96 hole black microwell plates, and add the above-mentioned sample of 20 μ L, mixing, is excitation wavelength with 450nm on multi-functional microplate reader again, and 480nm is an emission wavelength working sample fluorescence intensity.Fluorescence intensity is represented the aggregation extent of sample, and promptly high more its aggregation extent of fluorescence intensity is big more.The result is shown in Figure 3, compares with the A-beta42 that does not add antibody, and the A-beta42 fluorescence intensity behind the adding 0.25 and 1 μ M W8 obviously reduces (* P＜0.01), shows that W8 has the obvious suppression effect to the gathering of A-beta42.
Embodiment 9W8 is to the Cytotoxic restraining effect of A-beta42.
With the substratum that contains 10% foetal calf serum (MEM) neuroblastoma (SH-SY5Y) is made into the individual cells suspension, with 7000 cell inoculations in every hole to 96 porocyte culture plates, every pore volume 100 μ L.Cell was in 37 ℃ of cultivations 24 hours, and incubator CO2 concentration is 5%.Every hole adds sample, is divided into three groups, is respectively: the mixture of A-beta42 and scFv W8, A-beta42 organize and the cell that do not add sample as control group, the proteic final concentration of A-beta42 is 1 μ mol/L, the final concentration of scFv W8 also is 1 μ mol/L.
Cell continues to cultivate after 48 hours, and every hole adds MTT solution (5mg/mL) 10 μ L, hatches 3 hours for 37 ℃, stop cultivating, every hole adds 100mol/L MTT lysate (the 0.01N HCl that contains 10%SDS and 5% isopropylcarbinol), and 37 ℃ of overnight incubation are fully dissolved crystallisate.Select the 450nm wavelength, on enzyme-linked immunosorbent assay instrument, measure each hole absorbance value.Is ordinate zou with each absorbance value of adding behind the sample divided by the absorbance value that does not add sample, statistics as shown in Figure 4, the adding pair cell of A-beta42 produces tangible toxicity, and W8 can suppress this cytotoxicity (* P＜0.05).
Antibody W8-1, W8-2 activity experiment that embodiment 10 antibody W8 sudden change forms
According to the previous experiments method, the antibody W8-1 (its aminoacid sequence is shown in SEQ ID NO.8), the W8-2 (its aminoacid sequence is shown in SEQ IDNO.9) that antibody W8 are replaced with its indivedual amino acid mutations and form, carry out gathering test and the neurocyte toxicity test of A β, the result shows that W8-1, W8-2 can effectively suppress the fibrosis gathering of A β equally and obviously reduce the toxic action of A β to neuroblastoma cell SH-SY5Y.With W8-1, W8-2 as identification antibody, with enzyme-linked immunosorbent assay (ELISA) or immunodotting (Dot-blot) as experimental technique, with horseradish peroxidase (HRP) mark can with the 9E10 of W8 specific combination as second antibody, can detect the A beta oligomers of nM level in the sample equally respectively.
SEQUENCE LISTING
＜110〉Tsing-Hua University
＜120〉with A-beta oligomer specificity bonded gene engineering monoclonal antibody
<130>090105
<160>11
<170>PatentIn version 3.5
<210>1
<211>5
<212>PRT
<213>VH-CDR1
<400>1
Ser Tyr Ala Met Ser
1 5
<210>2
<211>17
<212>PRT
<213>VH-CDR2
<400>2
Ala Ile Ser Asn Arg Gly Met Gln Thr Glu Tyr Ala Asp Ser Val Lys
1 5 10 15
Gly
<210>3
<211>7
<212>PRT
<213>VH-CDR3
<400>3
Lys Ser Gly Thr Phe Asp Tyr
1 5
<210>4
<211>11
<212>PRT
<213>VL-CDR1
<400>4
Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn
1 5 10
<210>5
<211>7
<212>PRT
<213>VL-CDR2
<400>5
His Ala Ser Leu Leu Gln Ser
1 5
<210>6
<211>9
<212>PRT
<213>VL-CDR3
<400>
Gln Gln Gln Arg Arg Arg Pro Val Thr
1 5
<210>7
<211>246
<212>PRT
<213>antibody W8
<400>7
Ala Met Ala Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln
1 5 10 15
Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe
20 25 30
Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu
35 40 45
Glu Trp Val Ser Ala Ile Ser Asn Arg Gly Met Gln Thr Glu Tyr Ala
50 55 60
Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn
65 70 75 80
Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val
85 90 95
Tyr Tyr Cys Ala Lys Lys Ser Gly Thr Phe Asp Tyr Trp Gly Gln Gly
100 105 110
Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly
115 120 125
Ser Gly Gly Gly Gly Ser Thr Asp Ile Gln Met Thr Gln Ser Pro Ser
130 135 140
Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala
145 150 155 160
Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly
165 170 175
Lys Ala Pro Lys Leu Leu Ile Tyr His Ala Ser Leu Leu Gln Ser Gly
180 185 190
Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu
195 200 205
Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln
210 215 220
Gln Gln Arg Arg Arg Pro Val Thr Phe Gly Gln Gly Thr Lys Val Glu
225 230 235 240
Ile Lys Arg Ala Ala Ala
245
<210>8
<211>246
<212>PRT
<213>antibody W8-1
<400>8
Ala Met Ala Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln
1 5 10 15
Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe
20 25 30
Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu
35 40 45
Glu Trp Val Ser Ala Ile Ser Asn Arg Gly Met Gln Thr Glu Tyr Ala
50 55 60
Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn
65 70 75 80
Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val
85 90 95
Tyr Tyr Cys Ala Lys Lys Ser Gly Thr Phe Asp Tyr Trp Gly Gln Gly
100 105 110
Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly
115 120 125
Ser Gly Gly Gly Gly Ser Thr Asp Ile Gln Met Thr Gln Ser Pro Ser
130 135 140
Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala
145 150 155 160
Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Asn Gln Lys Pro Gly
165 170 175
Lys Ala Pro Lys Leu Leu Ile Tyr His Ala Ser Leu Leu Gln Ser Gly
180 185 190
Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu
195 200 205
Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln
210 215 220
Gln Gln Arg Arg Arg Pro Val Thr Phc Gly Gln Gly Thr Lys Val Glu
225 230 235 240
Ile Lys Arg Ala Ala Ala
245
<210>9
<211>246
<212>PRT
<213>antibody W8-2
<400>9
Ala Met Ala Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln
1 5 10 15
Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe
20 25 30
Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu
35 40 45
Glu Trp Val Ser Ala Ile Ser Asn Arg Gly Met Gln Thr Glu Tyr Ala
50 55 60
Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn
65 70 75 80
Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val
85 90 95
Tyr Tyr Cys Ala Lys Lys Ser Gly Thr Phe Asp Tyr Trp Gly Gln Gly
100 105 110
Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly
115 120 125
Ser Gly Gly Gly Gly Ser Thr Asp Ile Gln Met Thr Gln Ser Pro Ser
130 135 140
Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Leu
145 150 155 160
Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly
165 170 175
Lys Ala Pro Lys Leu Leu Ile Tyr Ser Ala Ser Leu Leu Gln Ser Gly
180 185 190
Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu
195 200 205
Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln
210 215 220
Gln Gln Arg Arg Arg Pro Val Thr Phe Gly Gln Gly Thr Lys Val Glu
225 230 235 240
Ile Lys Arg Ala Ala Ala
245
<210>10
<211>17
<212>DNA
＜213〉primer LMB3
<400>10
caggaaacag ctatgac 17
<210>11
<211>17
<212>DNA
＜213〉primer pHEN seq
<400>11
ctatgcggcc ccattca 17
Claims (10)
1. monoclonal antibody, it is characterized in that, its variable region of light chain contains the aminoacid sequence shown in SEQ ID NO.1, SEQ IDN0.2 and the SEO ID NO.3, and variable region of heavy chain contains the aminoacid sequence shown in SEQ ID NO.4, SEQ ID NO.5 and the SEQ ID NO.6.
2. monoclonal antibody according to claim 1 is characterized in that, is humanized antibody.
3. monoclonal antibody according to claim 1 is characterized in that, is single-chain antibody.
4. monoclonal antibody according to claim 3, the protein of forming by its aminoacid sequence shown in the SEQ ID NO.7, or by the aminoacid sequence shown in the SEQ ID NO.7 through replacement, disappearance or add that one or several is amino acid derived and have specificity in conjunction with the active protein of A-beta oligomer.
5. monoclonal antibody according to claim 4, its aminoacid sequence is shown in SEQ ID NO.8.
6. monoclonal antibody according to claim 4, its aminoacid sequence is shown in SEQ ID NO.9.
7. monoclonal antibody according to claim 4 is characterized in that, is the coli strain generation of CGMCCNo.2819 by deposit number.
8. the application of each described monoclonal antibody of claim 1 to 7 in preparation detection A-beta oligomer reagent.
9. each described monoclonal antibody of claim 1 to 7 is preparing the anti-ageing year purposes in the dementia medicine.
10. a pharmaceutical composition is characterized in that, contains each the described monoclonal antibody of claim 1-7 and the pharmaceutically acceptable carrier of significant quantity.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009100769959A CN101463085B (en) | 2009-01-16 | 2009-01-16 | Gene engineering monoclonal antibody combined with A-beta oligomer specificity |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009100769959A CN101463085B (en) | 2009-01-16 | 2009-01-16 | Gene engineering monoclonal antibody combined with A-beta oligomer specificity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101463085A CN101463085A (en) | 2009-06-24 |
| CN101463085B true CN101463085B (en) | 2011-09-14 |
Family
ID=40803903
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009100769959A Expired - Fee Related CN101463085B (en) | 2009-01-16 | 2009-01-16 | Gene engineering monoclonal antibody combined with A-beta oligomer specificity |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101463085B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107042092A (en) * | 2017-02-23 | 2017-08-15 | 南昌大学 | Affine sorbing material based on specific recognition c Myc label single domain heavy chain antibodies |
| CN107042091A (en) * | 2017-02-23 | 2017-08-15 | 南昌大学 | Affine in immunity sorbing material based on specific recognition c Myc label nano antibodies |
| CN107051397A (en) * | 2017-02-23 | 2017-08-18 | 南昌大学 | The affine in immunity sorbing material of specific recognition c Myc label nano antibodies |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1649623A (en) * | 2002-02-28 | 2005-08-03 | 明德赛特生物制药美国公司 | Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof |
| CN1685236A (en) * | 2002-09-27 | 2005-10-19 | 詹森药业有限公司 | N-11 truncated amyloid-beta monoclonal antibodies, compositions, methods and uses |
| CN1798766A (en) * | 2003-05-30 | 2006-07-05 | 神经实验室有限公司 | Humanized antibodies that recognize beta amyloid peptide |
| CN101325972A (en) * | 2005-12-12 | 2008-12-17 | Ac免疫有限公司 | A beta 1-42 specific monoclonal antibodies with therapeutic properties |
-
2009
- 2009-01-16 CN CN2009100769959A patent/CN101463085B/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1649623A (en) * | 2002-02-28 | 2005-08-03 | 明德赛特生物制药美国公司 | Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof |
| CN1685236A (en) * | 2002-09-27 | 2005-10-19 | 詹森药业有限公司 | N-11 truncated amyloid-beta monoclonal antibodies, compositions, methods and uses |
| CN1798766A (en) * | 2003-05-30 | 2006-07-05 | 神经实验室有限公司 | Humanized antibodies that recognize beta amyloid peptide |
| CN101325972A (en) * | 2005-12-12 | 2008-12-17 | Ac免疫有限公司 | A beta 1-42 specific monoclonal antibodies with therapeutic properties |
Non-Patent Citations (1)
| Title |
|---|
| Edward B. Lee et al..Targeting Amyloid-β Peptide (Aβ) Oligomers by Passive Immunization with a Conformation-selective Monoclonal Antibody Improves Learning and Memory in Aβ recursor Protein (APP) Transgenic Mice.《THE JOURNAL OF BIOLOGICAL CHEMISTRY》.2005, * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101463085A (en) | 2009-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101463082B (en) | Gene engineering monoclonal antibody combined with A-beta oligomer specificity | |
| TWI796328B (en) | B7-h3 antibody, antigen-binding fragment thereof and medical application thereof | |
| JP7524065B2 (en) | Anti-TIGIT antibodies and uses thereof | |
| KR102695287B1 (en) | Anti-phf-tau antibodies and uses thereof | |
| CA2122732C (en) | Multivalent antigen-binding proteins | |
| RU2558301C2 (en) | Polypeptides for bonding with "receptor of advanced glycation endproducts", their compositions and methods, which they take part in | |
| TW201610153A (en) | Gram-positive bacteria specific binding compounds | |
| KR20220154140A (en) | PVRIG binding proteins and their medical uses | |
| CN101983208A (en) | Glucagon receptor antagonists | |
| JP2012506695A (en) | Modified anti-IL-13 antibodies, compositions, methods, and uses | |
| TW201348256A (en) | CX3CR1-binding polypeptides | |
| BR112019025048A2 (en) | anti-cd40 antibody, fragment of binding to the antigen thereof, and medical use thereof | |
| JP7297090B2 (en) | Bifunctional fusion proteins for PDL1 and TGFβ and uses thereof | |
| TWI779307B (en) | ANTI-EphA4 ANTIBODY | |
| KR20220131935A (en) | Anti-ANGPTL3 antibodies and uses thereof | |
| WO2015160858A2 (en) | Antigen binding proteins that bind wisp1 | |
| CN101463085B (en) | Gene engineering monoclonal antibody combined with A-beta oligomer specificity | |
| CN104379741A (en) | Anti-human cd69 antibody, and use thereof for medical purposes | |
| CN101463084B (en) | Gene engineering monoclonal antibody combined with A-beta oligomer specificity | |
| WO2009084671A1 (en) | Human anti-α9 integrin antibody | |
| WO2013078223A1 (en) | Anti-factor h binding protein antibodies and methods of use thereof | |
| CN101463083B (en) | Gene engineering monoclonal antibody combined with A-beta oligomer specificity | |
| WO2020063823A1 (en) | Anti-pd-1 antibodies and uses thereof | |
| KR102053749B1 (en) | An antibody specific for Neisseria gonorrhoeae and the use thereof | |
| US20230303690A1 (en) | Novel anti-lag3 antibodies and methods of making and using the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110914 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |